# Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients

> **NCT04843553** · EARLY_PHASE1 · COMPLETED · sponsor: **Rhode Island Hospital** · enrollment: 30 (actual)

## Conditions studied

- Actinic Keratoses

## Interventions

- **DRUG:** Oral Nicotinamide

## Key facts

- **NCT ID:** NCT04843553
- **Lead sponsor:** Rhode Island Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-14
- **Primary completion:** 2019-02-08
- **Final completion:** 2020-12-18
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04843553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04843553, "Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04843553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*